Short Interest in Mangoceuticals, Inc. (NASDAQ:MGRX) Drops By 65.1%

Posted by Donna Armstrong on Sep 14th, 2026

Mangoceuticals, Inc. (NASDAQ:MGRX – Get Free Report) was the recipient of a large decrease in short interest in August. As of August 31st, there was short interest totaling 632,502 shares, a decrease of 65.1% from the August 15th total of 1,812,630 shares. Based on an average daily trading volume, of 861,529 shares, the days-to-cover ratio is presently 0.7 days. Approximately 3.5% of the company’s shares are short sold.

Mangoceuticals Trading Up 1.8%

Shares of Mangoceuticals stock traded up $0.01 on Monday, reaching $0.41. 541,581 shares of the company were exchanged, compared to its average volume of 582,990. The company has a market capitalization of $8.84 million, a price-to-earnings ratio of -0.41 and a beta of 2.04. Mangoceuticals has a one year low of $0.16 and a one year high of $2.75. The company has a 50-day moving average of $0.44 and a 200 day moving average of $0.41.

Mangoceuticals (NASDAQ:MGRX – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $0.08 million for the quarter. Mangoceuticals had a negative return on equity of 96.39% and a negative net margin of 4,794.60%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Wall Street Zen raised Mangoceuticals to a “sell” rating in a research note on Saturday, July 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Mangoceuticals in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

View Our Latest Report on MGRX

Mangoceuticals Company Profile

(Get Free Report)

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.